ICPT
Intercept Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 19.00
- Prev close
- 19.00
- Mkt cap
- 794.69M
- Vol
- 3.91M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.98
- High
- 19.01
- Forward P/E
- 8.88
- Beta
- 0.88
- Short ratio
- 5.54
- Inst. own
- 81.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2023
- 50-d avg
- 16.63
- 200-d avg
- 14.55
- 1y target
- 19.00
Key statistics
- Market cap
- 794.69M
- Enterprise value
- 695.84M
- Trailing P/E
- 0.00
- Forward P/E
- 8.88
- PEG ratio
- 1.78
- Price / sales
- 2.50
- Price / book
- 11.06
- EPS (TTM)
- -1.09
- Beta
- 0.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -19.39%
- Revenue (TTM)
- 317.68M
- Revenue growth
- 14.40%
- Free cash flow
- -42.40M
- Total cash
- 322.71M
- Total debt
- 223.86M
- Return on equity
- -64.02%
- Shares outstanding
- 41.83M
- Short % of float
- 25.19%
- 50-day average
- 16.63
- 200-day average
- 14.55
Analyst view
Consensus: hold
- Strong buy3
- Buy7
- Hold8
- Sell2
- Strong sell0
Next earnings
Nov 6, 2023
Expected Nov 6, 2023. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2023 | Sep 1, 2023 | -0.27 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.56 | — | — | — |
| Apr 27, 2023 | Mar 1, 2023 | -0.57 | — | — | — |
| Mar 2, 2023 | Dec 1, 2022 | -0.53 | — | — | — |
| Nov 1, 2022 | Sep 1, 2022 | 5.11 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | -0.53 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 26, 2023 | Canaccord Genuity | down | Buy | Hold |
| Sep 26, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 26, 2023 | RBC Capital | main | Sector Perform | Sector Perform |
| Sep 26, 2023 | B. Riley Securities | down | Buy | Neutral |
| Aug 2, 2023 | Canaccord Genuity | main | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- interceptpharma.com
News
- Intercept Pharma withdraws liver disease drug from US market
- US FDA says Intercept's drug can cause liver injury in patients without scarring
- US FDA declines full approval for Intercept's liver disease drug
- Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
- FDA advisers vote against confirmatory data for Intercept's liver disease drug
- FDA staff raises efficacy concerns over Intercept's liver disease drug
- Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review
- Gilead (GILD) Announces Positive Interim Results on PBC Drug
- Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
- Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Your note
Sign in to keep a note on ICPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Stock Award(Grant) | May 23, 2023 | 686,686 |
| BERREY M MICHELLE | Officer | Stock Award(Grant) | Jan 26, 2023 | 83,877 |
| BRADBURY DANIEL M | Director | Stock Award(Grant) | May 23, 2023 | 39,471 |
| FUNDARO PAOLO | Director | Stock Award(Grant) | May 23, 2023 | 43,905 |
| GOTTESDIENER KEITH MICHAEL | Director | Stock Award(Grant) | May 23, 2023 | 32,830 |
| LUCA BENATTI | Director | Stock Award(Grant) | May 23, 2023 | 33,598 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 11.23% | 4,693,817 | 51.91M | Jun 29, 2023 |
| Blackrock Inc. | 10.52% | 4,396,970 | 48.63M | Jun 29, 2023 |
| State Street Corporation | 10.00% | 4,180,224 | 46.23M | Jun 29, 2023 |
| Deerfield Management Company, L.P. (Series C) | 4.97% | 2,077,893 | 22.98M | Jun 29, 2023 |
| UBS Group AG | 3.25% | 1,359,471 | 15.04M | Jun 29, 2023 |
| Caligan Partners, LP | 3.10% | 1,293,510 | 14.31M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.31% | 3,473,737 | 37.62M | Aug 30, 2023 |
| Vanguard Strategic Equity Fund | 3.16% | 1,320,226 | 14.60M | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.69% | 1,123,441 | 12.43M | Jun 29, 2023 |
| Vanguard Explorer Fund, Inc. | 2.09% | 873,648 | 9.44M | Jul 30, 2023 |
| iShares Russell 2000 ETF | 1.35% | 563,326 | 6.10M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.21% | 504,099 | 5.58M | Jun 29, 2023 |